Faeth Therapeutics (NASDAQ: FTH) has a big catalyst coming before the end of the year. And the FDA just made it a little more interesting.

‍

The company is currently testing an experimental cancer treatment called PIKTOR in patients with advanced endometrial cancer who have already run out of several treatment options. Topline Phase 2 results are expected before the end of 2026, and those numbers could go a long way toward determining whether PIKTOR becomes Faeth's most valuable asset.

‍

Now the FDA has granted the treatment Fast Track designation, which is designed to speed development and regulatory review for drugs targeting serious diseases with unmet medical needs.

‍

Make no mistake: Fast Track designation doesn't mean the drug works, and it certainly doesn't guarantee FDA approval. But for a small biotech approaching an important clinical readout, it does matter. It gives Faeth more frequent access to the FDA and potentially creates a faster regulatory path if the upcoming data are strong.

‍

Here's what PIKTOR actually does

‍

Cancer drugs can get complicated pretty quickly, so here's the simple version.

‍

PIKTOR combines two oral drugs, serabelisib and sapanisertib, designed to block multiple parts of what's known as the PI3K/AKT/mTOR pathway. That pathway essentially acts like a signaling system telling cells when to grow and survive.

‍

The problem is that in many cancers, those signals get stuck in the "on" position.

‍

In fact, the pathway is believed to be dysregulated in as many as 50% of all solid tumors. Previous drugs have generally targeted individual parts of the pathway. PIKTOR simultaneously targets PI3K-alpha, mTORC1, and mTORC2, with the idea that blocking several points at once may make it more difficult for cancer cells to find another route to keep growing.

‍

The next data could move the stock

‍

Faeth is now combining PIKTOR with the chemotherapy drug paclitaxel in its Phase 2 endometrial cancer trial. And this is where things get interesting.

‍

The Phase 2 study is relatively small, enrolling approximately 40 patients, and its primary endpoint is objective response rate. Put simply, researchers want to know how many patients experience meaningful tumor shrinkage after receiving PIKTOR plus paclitaxel.

‍

Positive results could do several things.

‍

First, they would provide human clinical evidence supporting Faeth's multi-node approach. Second, they could strengthen the company's case for advancing PIKTOR into larger studies. And with Fast Track designation now in hand, strong data could allow Faeth to work more closely with the FDA on what comes next.

‍

But there's another reason you should pay attention.

‍

PIKTOR isn't limited to endometrial cancer.

‍

Faeth is also testing the drug in HR-positive/HER2-negative advanced breast cancer, where the first patient was dosed in April. Interim results from that Phase 1b/2 study are expected in 2027. If PIKTOR demonstrates activity across multiple cancers, its potential value could increase considerably.

‍

Faeth has money to reach the readouts

‍

For a clinical-stage biotech, promising science doesn't mean much if the company runs out of money before producing the data.

‍

Faeth appears to be in decent shape on that front.

‍

The company raised approximately $200 million in gross proceeds through a private placement completed alongside the acquisition of Faeth earlier this year. As of March 31, it had $202.8 million in cash, cash equivalents, and marketable securities, which management said should be sufficient to fund operations through the topline readouts from both the endometrial and breast cancer programs.

‍

That's important because it reduces the immediate risk that Faeth will need to raise additional capital before reaching its major clinical catalysts.

‍

Of course, none of this eliminates the considerable risk that comes with owning a clinical-stage biotech. Faeth doesn't have an approved drug, and disappointing Phase 2 results could hit the stock hard.

‍

But that's also why the next few months matter so much.

‍

Fast Track designation gives PIKTOR some additional regulatory momentum. The balance sheet gives Faeth enough capital to reach its upcoming readouts. And the endometrial cancer data should give investors their clearest indication yet of whether the company's approach actually works in patients.

‍

For now, Fast Track is encouraging. But the Phase 2 numbers coming later this year are what could really determine where Faeth goes from here.

‍